Conference Description:

Advance the Targeting of Non-Coding RNAs by Enhancing Target Specificity, Optimizing Formulation & Improving Efficacy for the Accelerated Translation of Safe & Effective Non-Coding RNA Therapeutics

As the RNA revolution continues off the back of the COVID-19 pandemic, large pharma and investors turn their attention to emerging non-coding RNA therapies beyond just mRNA.

Built with world-class biopharmaceutical industry insights, this industry-, therapeutic- and translational-focused meeting will set the scene for non-coding RNAs, such as lncRNAs and microRNAs, for their successful development into the clinic.

Expertise from new and emerging companies in this rapidly growing space will cover the identification, validation and development of nucleic acid targeting approaches of non-coding RNAs in broad range of diseases.

Tickets https://go.evvnt.com/1259185-2 ?pid=154

Prices:
Drug Developer Pricing (Conference + 2 Workshops) USD 2797.00
Drug Developer Pricing (Conference + 1 Workshop) USD 2398.00
Drug Developer Pricing (Conference Only) USD 1999.00
Academic Pricing (Conference + 2 Workshops) USD 2397.00
Academic Pricing (Conference + 1 Workshop) USD 2098.00
Academic Pricing (Conference Only) USD 1899.00
Solution Provider Pricing (Conference + 2 Workshops) USD 3497.00
Solution Provider Pricing (Conference + 1 Workshop) USD 2998.00
Solution Provider Pricing (Conference Only) USD 2499.00

Speakers: Thomas Chappie, Associate Research Fellow, Pfizer, Dominique Verhelle, Co-Founder & CEO, NextRNA Therapeutics, Samir Ounzain, Co-founder, CEO & Board Director, HAYA Therapeutics, Robert MacLeod, CSO, Flamingo Therapeutics, Thomas Thum, Founder & CSO, Cardior Pharmaceuticals, Michel Janicott, Chief Development Officer, inteRNA Technologies, Denis Drygin, CSO, Regulus Therapeutics, Anwar Hossain, Principal Scientist, MD Anderson Cancer Center, David Spector, Professor & Director of Research, Cold Spring Harbor Laboratories, Ranjan Perera, Director RNA Center & Associate Professor, John Hopkins University, Stephanie Fanucchi, CSO, Lemba Therapeutics, Rabia Khan, Founder & CEO, Ladder Therapeutics, Mansoor Amiji, University Distinguished Professor, Professor of Pharmaceutical Sciences, & Professor of Chemical Engineering, Northeastern Univeristy, Janika Viereck, Head of Research, Cardior Pharmaceuticals, Michael Garrett, CEO, Flamingo Therapeutics, Zachary Singer, CEO, Lemba Therapeutics, Pieter Mestdagh, Professor; Principal Scientist, Ghent University; CellCarta, David Bumcrot, CSO, CAMP4 Therapeutics

Dates and Time: Starts: Tue, Nov 8, 2022 ( 8:00 AM) and Ends: Thu, Nov 10, 2022 ( 4:00 PM)